Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,759.00-1.92%ETH$2,449.71-0.78%GOLD$4,364.00-0.98%OIL$103.08+0.59%
Smart Investors Daily
SP

NASDAQ · SPRY

ARS Pharmaceuticals, Inc.

Healthcare · Biotechnology

$5.23

Down-$0.17 (-3.25%)

Updated Sep 11, 2026, 12:40 AM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.1B
P/E ratio
-13.85
Dividend yield
0.00%
52-week range
$4.91 – $10.87
Volume
874.55K
Avg. volume
2.29M

Price performance

SPRY price history

1M range · 0 trading sessions · Daily adjusted prices

SPRY does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest SPRY news

The latest Smart Investors Daily articles mentioning SPRY.

Stock researchCompany · Overview

SPRY research

Overview

Company profile and research snapshot.

Company profile

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$31.00
Implied upside
—
Analysts
—
SPRY recent ratings
DateFirmRatingTarget
Jun 25, 2026Leerink PartnersOutperform—
May 28, 2026Cantor FitzgeraldOverweight—
Sep 4, 2025Roth CapitalBuy—
Mar 7, 2025ScotiabankSector Outperform—
Jan 14, 2025Raymond JamesStrong Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

ARS Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences. Wells Fargo Healthcare Conference 1x1 Investor Meetings: Wednesday, September 9, 2026Location: Boston Cantor Global Healthcare Conference Fireside Chat: Fr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By